187 related articles for article (PubMed ID: 22302417)
21. Abatacept as add-on therapy for rheumatoid arthritis.
Allison C
Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
[TBL] [Abstract][Full Text] [Related]
22. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.
Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC
Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911
[TBL] [Abstract][Full Text] [Related]
23. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
Sherrer Y
Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
[TBL] [Abstract][Full Text] [Related]
24. Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.
Alten R; Kaine J; Keystone E; Nash P; Delaet I; Genovese MC
Arthritis Rheumatol; 2014 Aug; 66(8):1987-97. PubMed ID: 24782324
[TBL] [Abstract][Full Text] [Related]
25. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
Barr C
J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.
Haggerty HG; Abbott MA; Reilly TP; DeVona DA; Gleason CR; Tay L; Dodge R; Aranda R
J Rheumatol; 2007 Dec; 34(12):2365-73. PubMed ID: 18050376
[TBL] [Abstract][Full Text] [Related]
27. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous abatacept in rheumatoid arthritis: current update.
Keystone E; Alkhalaf A; Makkawy M
Expert Opin Biol Ther; 2015; 15(8):1221-30. PubMed ID: 26160492
[TBL] [Abstract][Full Text] [Related]
29. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
30. Short- and long-term efficacy of intra-articular injections with betamethasone as part of a treat-to-target strategy in early rheumatoid arthritis: impact of joint area, repeated injections, MRI findings, anti-CCP, IgM-RF and CRP.
Hetland ML; Østergaard M; Ejbjerg B; Jacobsen S; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Svendsen A; Pedersen JK; Skjødt H; Ellingsen T; Lindegaard H; Pødenphant J; Hørslev-Petersen K;
Ann Rheum Dis; 2012 Jun; 71(6):851-6. PubMed ID: 22302316
[TBL] [Abstract][Full Text] [Related]
31. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
Reynolds J; Shojania K; Marra CA
Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study.
Matsubara T; Yamana S; Tohma S; Takeuchi T; Kondo H; Kohsaka H; Ozaki S; Hashimoto H; Miyasaka N; Yamamoto A; Hiraoka M; Abe T
Mod Rheumatol; 2013 Jul; 23(4):634-45. PubMed ID: 22833376
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
35. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
36. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous abatacept for the treatment of rheumatoid arthritis.
Schiff M
Rheumatology (Oxford); 2013 Jun; 52(6):986-97. PubMed ID: 23463804
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study.
Westhovens R; Kremer JM; Emery P; Russell AS; Alten R; Barré E; Dougados M
Clin Exp Rheumatol; 2014; 32(4):553-62. PubMed ID: 25005467
[TBL] [Abstract][Full Text] [Related]
39. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
[TBL] [Abstract][Full Text] [Related]
40. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
